52 related articles for article (PubMed ID: 21496891)
1. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Krivak TC; Darcy KM; Tian C; Bookman M; Gallion H; Ambrosone CB; Deloia JA
Gynecol Oncol; 2011 Jul; 122(1):121-6. PubMed ID: 21496891
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Bookman MA; Brady MF; McGuire WP; Harper PG; Alberts DS; Friedlander M; Colombo N; Fowler JM; Argenta PA; De Geest K; Mutch DG; Burger RA; Swart AM; Trimble EL; Accario-Winslow C; Roth LM
J Clin Oncol; 2009 Mar; 27(9):1419-25. PubMed ID: 19224846
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Moore KN; Tritchler D; Kaufman KM; Lankes H; Quinn MCJ; ; Van Le L; Berchuck A; Backes FJ; Tewari KS; Lee RB; Kesterson JP; Wenham RM; Armstrong DK; Krivak TC; Bookman MA; Birrer MJ
Gynecol Oncol; 2017 Nov; 147(2):396-401. PubMed ID: 28935272
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
5. Functional Polymorphisms at ERCC1/XPF Genes Confer Neuroblastoma Risk in Chinese Children.
Zhuo ZJ; Liu W; Zhang J; Zhu J; Zhang R; Tang J; Yang T; Zou Y; He J; Xia H
EBioMedicine; 2018 Apr; 30():113-119. PubMed ID: 29544698
[TBL] [Abstract][Full Text] [Related]
6. Variants in Notch signalling pathway genes, PSEN1 and MAML2, predict overall survival in Chinese patients with epithelial ovarian cancer.
Xu Y; Cheng L; Dai H; Zhang R; Wang M; Shi T; Sun M; Cheng X; Wei Q
J Cell Mol Med; 2018 Oct; 22(10):4975-4984. PubMed ID: 30055028
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 and ERCC2 polymorphisms and adult glioma.
Wrensch M; Kelsey KT; Liu M; Miike R; Moghadassi M; Sison JD; Aldape K; McMillan A; Wiemels J; Wiencke JK
Neuro Oncol; 2005 Oct; 7(4):495-507. PubMed ID: 16212814
[TBL] [Abstract][Full Text] [Related]
8. Genotyping, in silico screening and molecular dynamics simulation of SNPs of MGMT and ERCC1 gene in lung cancer patients treated with platinum-based doublet chemotherapy.
Singh S; Gupta A; Singh N; Sengupta PS; Panda SK; Sharma S
J Biomol Struct Dyn; 2023 Sep; ():1-20. PubMed ID: 37771161
[TBL] [Abstract][Full Text] [Related]
9. Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer.
Huang X; Li J; Pang X; Zhu J; Pan J; Li Y; Tang J
Clin Transl Sci; 2023 Dec; 16(12):2519-2529. PubMed ID: 38013655
[TBL] [Abstract][Full Text] [Related]
10. Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
Obermayr E; Mohr T; Schuster E; Braicu EI; Taube E; Sehouli J; Vergote I; Pujade-Lauraine E; Ray-Coquard I; Harter P; Wimberger P; Joly-Lobbedez F; Mahner S; Moll UM; Concin N; Zeillinger R
Int J Cancer; 2024 Apr; ():. PubMed ID: 38676430
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas.
Bandala-Jacques A; Hernández-Cruz IA; Castro-Hernández C; Díaz-Chávez J; Arriaga-Canon C; Barquet-Muñoz SA; Prada-Ortega DG; Cantú-de León D; Herrera LA
Rev Invest Clin; 2020 May; 73(3):. PubMed ID: 32488223
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer.
Pernar Kovač M; Tadić V; Kralj J; Duran GE; Stefanelli A; Stupin Polančec D; Dabelić S; Bačić N; Tomicic MT; Heffeter P; Sikic BI; Brozovic A
Cell Mol Life Sci; 2023 Sep; 80(10):294. PubMed ID: 37718345
[TBL] [Abstract][Full Text] [Related]
13. Clinical Perspectives of ERCC1 in Bladder Cancer.
Koutsoukos K; Andrikopoulou A; Dedes N; Zagouri F; Bamias A; Dimopoulos MA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266377
[TBL] [Abstract][Full Text] [Related]
14. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
15. DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
Tomasova K; Cumova A; Seborova K; Horak J; Koucka K; Vodickova L; Vaclavikova R; Vodicka P
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32605254
[TBL] [Abstract][Full Text] [Related]
16.
Yoshihama T; Fukunaga K; Hirasawa A; Nomura H; Akahane T; Kataoka F; Yamagami W; Aoki D; Mushiroda T
Oncotarget; 2018 Jul; 9(51):29789-29800. PubMed ID: 30038720
[TBL] [Abstract][Full Text] [Related]
17. FBP1 promotes ovarian cancer development through the acceleration of cell cycle transition and metastasis.
Xiong X; Zhang J; Hua X; Cao W; Qin S; Dai L; Liu W; Zhang Z; Li X; Liu Z
Oncol Lett; 2018 Aug; 16(2):1682-1688. PubMed ID: 30008853
[TBL] [Abstract][Full Text] [Related]
18. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer.
Herzog TJ; Spetzler D; Xiao N; Burnett K; Maney T; Voss A; Reddy S; Burger R; Krivak T; Powell M; Friedlander M; McGuire W
Oncotarget; 2016 Apr; 7(15):19840-9. PubMed ID: 26942886
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
Lee MS; Liu CY; Su L; Christiani DC
Lung Cancer; 2015 Jul; 89(1):8-12. PubMed ID: 26001533
[TBL] [Abstract][Full Text] [Related]
20. Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.
Lambrechts S; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Smeets D; Debruyne PR; Renard V; Vroman P; Luyten D; Neven P; Amant F; Leunen K; Vergote I;
BMC Pharmacol Toxicol; 2015 Feb; 16():2. PubMed ID: 25881102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
